Day: March 2, 2020

March 2, 2020Global survey reveals 36% have slept separately from their bed partner in an attempt to improve sleep74% admit to using cell phones in bed60% agree they are interested in new information or strategies to help them get better sleep       Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the findings from its 5th annual sleep survey in a report, “Wake Up Call: Global Sleep Satisfaction Trends.” Philips surveyed more than 13,000 adults in 13 countries to capture attitudes, perceptions, and behaviors around sleep. This year’s results show global sleep satisfaction remains low with worry/stress, relationships and cell phone use reported as key sleep inhibitors.Worry and stress continue to affect a good night’s sleepOnly 49% of people are satisfied [1] with...

TEL AVIV, Israel, March 02, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 19 at 8:30am Eastern Time to report fourth quarter and year ended December 31, 2019 financial results and to provide a corporate update.About VBLVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide...

— On track to complete rolling NDA submission to the FDA for setmelanotide in POMC and LEPR deficiency obesities in the first quarter of 2020 —— Granted orphan drug designation by the European Medicines Agency for setmelanotide in Alström syndrome —— Completed full enrollment in Phase 3 trial of setmelanotide in Bardet-Biedl and Alström syndromes in December; topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 —–Rhythm Phase 2 Basket study actively enrolling multiple cohorts across five rare MC4R pathway-related disorders with potential U.S. prevalence greater than 80,000 patients; data updates expected in 2020 —— Ongoing genetic sequencing efforts have sequenced more than 25,000 people with early-onset, severe obesity —BOSTON, March 02,...

SOLON, Ohio, March 02, 2020 (GLOBE NEWSWIRE) — Energy Focus, Inc. (NASDAQ:EFOI), a leader in advanced LED lighting technologies, will announce its quarterly results for the fourth quarter and year-ended December 31, 2019, premarket on Thursday, March 19 and host a conference call at 11 a.m. the same day to discuss the results for the fourth quarter and year-end.You can access the live conference call by dialing the following phone numbers: toll-free 1-877-451-6152 or international 1-201-389-0879, and referencing the conference ID# 13699827.The conference call will be simultaneously webcast. To listen to the webcast, log on to it at: http://public.viavid.com/index.php?id=138339. The webcast will be available at this link through April 2, 2020. Financial information presented on the call, including the earnings press release, will...

 Hamilton, Bermuda, March 2, 2020Dear Shareholders,We already referred to the Corona Virus in a  press release of  Friday January 31, 2020, stating that “we do not see any implications for NAT” – from the Virus.In the NAT Q4 2019 report of Tuesday February 18, 2020 we drew the same conclusion. We have learnt over the years that we do not necessarily see negative implications for NAT in times when there is political uncertainty.Political uncertainty may create positive implications for NAT. The last few years, irrespective of the Corona Virus, there are exports of crude oil from the USA. This development creates work for many suezmaxes of our type.  It is part of our business to handle risk. We have traded ships in Hormuz for decades – Hormuz in the Persian Gulf is an area between the adversaries Saudi Arabia and Iran of about 30 nautical...

TORONTO, March 02, 2020 (GLOBE NEWSWIRE) — Probe Metals Inc. (TSX-V: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to announce that it has entered into a definitive agreement of purchase and sale (the “Agreement”) with Monarch Gold Corporation (“Monarch”), pursuant to which Probe has agreed to acquire a 100% interest in the Monique Property (the “Property”), located 25 km east-southeast of Val-d’Or, Québec. As previously disclosed by Probe in January 2017, Probe had entered into an option agreement with Richmont Mines Inc. (which agreement was subsequently acquired by Monarch Gold Corporation) pursuant to which Probe had the right to earn a 60% interest in the Property by spending an aggregate of $2 million on exploration expenditures over 4 years.David Palmer, President and CEO of Probe, states: “The Monique property...

TORONTO, 02 mars 2020 (GLOBE NEWSWIRE) — Probe Metals Inc. (TSX-V : PRB) (OTCQB : PROBF) (« Probe » ou la « Société ») a le plaisir d’annoncer la signature d’une entente définitive d’achat et de vente (l’« entente ») avec Corporation Aurifère Monarques (« Monarques »), en vertu de laquelle Probe s’est engagé à acquérir une participation de 100 % dans la propriété Monique (la « propriété »), située à 25 kilomètres à l’est-sud-est de la ville de Val-d’Or au Québec. Tel qu’annoncé antérieurement par Probe en janvier 2017, Probe avait conclu une entente d’option avec Mines Richmont Inc. (entente qui a par la suite été acquise par Monarques), en vertu de laquelle Probe avait le droit d’acquérir une participation de 60 % dans la propriété en dépensant un montant total de 2 millions de dollars en exploration sur une période de 4 ans.David...

– Results from three clinical studies in 2019 support Phase 2 development program in urea cycle disorders (UCD) and advancement of hepatic encephalopathy program into next clinical study– Top-line data expected in Q4 2020 from Phase 2 trial of KB195 in patients with UCD and from multi-drug resistant pathogens clinical study of KB109LEXINGTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.“2019 was a transformational year for Kaleido as we validated our platform with patient clinical data, advanced our pipeline,...